Morphogenesis, Novartis Animal Health To Develop Cancer Immunotherapy For Companion Animals
Reportedly, the agreement gives Novartis exclusive rights to Morphogenesis’ proprietary canine and feline cancer cell lines as well as its patented cancer vaccine technology. Morphogenesis and Novartis will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.